Industry Outlook
The medical marijuana market is set to reach US$ 57,582.5 Mn by 2026 from US$ 13,908.7 Mn in 2017 at a compound annual growth rate (CAGR) of 17.1% during the forecast period from 2018 to 2026. According to the International Association for the Study of Pain (IASP) any pain persisting for more than six months in defined as chronic pain. The diseases in which the clinical manifestation is chronic pain are rheumatoid arthritis, psoriasis, ankylosing spondylitis, multiple sclerosis etc. Chronic pain affects approximately 30% to 50% of the world population.
In the last decade researchers throughout the globe have shown keen interest in understanding the therapeutic benefits of marijuana resulting in high content screening for compounds such as tetrahydrocannabinol, cannabidiol, cannabigerol, cannabidivarin etc., to treat chronic pain by stimulating the CB1 and CB2 receptors respectively. Healthcare agencies throughout the globe are drafting effective guidelines to legalize the production and sale of marijuana for medicinal purposes and stringent regulation and penalty has also been implemented for offenders using marijuana for recreational purposes.
Market Synopsis
Get a sample copy for more information
"Rising prevalence of patients suffering with cancer to drive the medical marijuana market"
According to the latest research citing of World Health Organization (WHO) cancer stands second for the cause of mortality in patients globally, approximately 1 in 6 deaths is due to cancer. The patients in the last stage of cancer and even patients receiving chemotherapy suffer with tremendous pain and nausea. In clinical trials studies Cannabinol has been found beneficial to address both concerns of cancer patients by stimulating the cannabinoid receptors CB1 and CB2 receptors. Chronic pain will garner good growth during the forecast period due to increasing number of geriatric patients suffering with musculoskeletal diseases such as osteoarthritis, rheumatoid arthritis and joint pains. Cannabinoids have also proven beneficial for its pain relieving effect in patients suffering with chronic pain due to psoriasis and multiple sclerosis.
Get a sample copy for more information
"Supportive regulatory environment and government approval to propel the sale of medical marijuana in hospital pharmacies"
A large number of patients suffering with chronic pain such as arthritis, migraine, multiple sclerosis, psoriasis and other autoimmune inflammatory diseases visit hospital pharmacies to avail for prescribed anti-inflammatory drugs. In the last decade government healthcare agencies have implemented jurisdiction to make marijuana available in hospital pharmacy to address the need of patients suffering with chronic pain, anorexia and nausea. Dispensaries will register impressive growth during the forecast period to cater the need of patients in suburban areas. Purchasing marijuana from dispensaries gives surety to patients that it is not adulterated and will have no deleterious health effects as pure Cannabis sativa strain is provided to the patient. Proper records regarding the patient information and the amount of marijuana dispensed in maintained on regular basis.
Get a sample copy for more information
"Rise in chronic pain and cancer in geriatric population to drive the medical marijuana market growth in North America"
North America currently dominates the medical marijuana market with 52% share. Rising prevalence of geriatric patients suffering with chronic pain and increasing number of patients suffering with cancer drive the medical marijuana market in North America. U.S. Food and Drug Administration (USFDA) has been proactive in understanding the medicinal requirement of marijuana in treating anorexia, and nausea by giving fast track drug approval. In Europe the approval of marijuana for medicinal purposes faces tremendous challenges as there is no unison among the local regulatory agencies. Since 2016, Germany has drafted regulatory guidelines for the production and sale of marijuana for medicinal purposes. Other European Union countries have started working on the same statutes adopted by Germany for growth of medical marijuana market in European Union. Rest of the world will be the fastest growing regional segment for the medical marijuana market on account of key factors largest production of legal marijuana (Cannabis sativa and Cannabis indica) in countries such as Afghanistan, Australia and South Asian countries. Rest of the world holds three fourths of the patients suffering with chronic pain and cancer. Regulatory agencies are working to legalize the sale of marijuana in hospital pharmacies and dispensaries for medicinal purposes.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Marker estimation and compounded annual growth rate for the report medical marijuana market was determined by quantitative analysis. The market segmentation consists of application, point of sale and geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2016-2026 |
| Base Year |
2017 |
| Forecast Period |
2018-2026 |
| Historical Year |
2016 |
| Unit |
USD Million |
| Segmentation |
By Application (2016–2026; US$ Mn)
• Chronic Pain
• Neurological Disorders
• Cancer
• Others (Anorexia, Nausea etc.)
|
|
By Point of Sale (2016–2026; US$ Mn)
• Online Pharmacy
• Dispensaries
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (United States and Canada)
• Europe (U.K., Germany, Rest of Europe)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Rest Of World (Australia, Israel,RoW)
|
Quantitative growth analysis was performed to perform the overall market assessment for medical marijuana market. Throughout the globe the regulatory and legal jurisdiction regarding the sale and production of marijuana is variegated and so in depth analysis pertaining to medical marijuana prescribed for medicinal purpose in different regional segments have been covered. Competitive landscape was studies to understand the existing competition prevailing in the medical marijuana market. Different types of marijuana products are mention in the product portfolio segment. The major players engaged in the legal production and sale of medical marijuana are AbbVie, Inc., CannaGrow Holdings, Inc., Canopy Growth Corporation, Inc., GW Pharmaceuticals, Plc. Insys Therapeutics, Inc., Novartis AG, Lexaria Corporation, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and United Cannabis Corporation.
Key questions answered in this report
- What is the market estimation and compounded annual growth rate (CAGR) for medical marijuana market?
- Who are the major players engaged in the production and sale of legal marijuana for medicinal purpose?
- What are the legal and regulatory prerequisites involved for the production and sale of medical marijuana?
- What are the drivers and restraints for medical marijuana market?
- Which is the leading and fastest growing application segment for medical marijuana market?
- Which is the leading and fastest growing point of sale for medical marijuana market?
- Which is the leading and fastest growing regional segment for medical marijuana market?
